Results 11 to 20 of about 9,430 (168)

Golimumab [PDF]

mAbs, 2009
Golimumab, a human anti-TNFalpha IgG1kappa monoclonal antibody, was approved in the US and Canada in April 2009 as a treatment for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, and is undergoing regulatory review in the EU for these indications.
Sohini, Mazumdar, David, Greenwald
  +5 more sources

Golimumab

Reactions Weekly, 2012
Hoofnagle JH.
europepmc   +3 more sources

Evaluation of Improvement in Skin and Nail Psoriasis in Bio‐naïve Patients With Active Psoriatic Arthritis Treated With Golimumab: Results Through Week 52 of the GO‐VIBRANT Study

ACR Open Rheumatology, 2020
Objective To evaluate whether intravenous (IV) golimumab produces improvements in skin and nail symptoms that are concomitant with improvements in quality of life (QoL) and joint symptoms in patients with psoriatic arthritis.
Philip Mease, M. Elaine Husni, Soumya D. Chakravarty, Shelly Kafka, Dennis Parenti, Lilianne Kim, Kim Hung Lo, Elizabeth C. Hsia, Arthur Kavanaugh   +8 more
doaj   +1 more source

Effect of Golimumab Dose Escalation in Japanese Patients With Rheumatoid Arthritis: Post-Hoc Analysis of Post-Marketing Surveillance Data

Rheumatology and Therapy, 2020
Introduction While dose escalation of golimumab has been used for patients with rheumatoid arthritis who demonstrate an inadequate response to the standard dose, its effectiveness has not been fully evaluated.
Hirohito Shimizu, Hisanori Kobayashi, Masayoshi Kanbori, Yutaka Ishii   +3 more
doaj   +1 more source

Effectiveness and Safety of Golimumab in Patients with Ulcerative Colitis: A Multicenter, Prospective, Postmarketing Surveillance Study

Gut and Liver, 2022
Background/Aims: Golimumab has been used for patients with ulcerative colitis (UC) since 2013. However, there is limited data on the effectiveness and safety of the real-world use of golimumab in Asian patients.
Jongwook Yu, Soo Jung Park, Hyung Wook Kim, Yun Jeong Lim, Jihye Park, Jae Myung Cha, Byong Duk Ye, Tae Oh Kim, Hyun-Soo Kim, Hyun Seok Lee, Su Young Jung, Youngdoe Kim, Chang Hwan Choi   +12 more
doaj   +1 more source

Association of Body Mass Index with SARS-CoV-2 Infection in Inflammatory Arthritis Patients Receiving Biologic Therapy: Singapore National Biologics Register Findings. [PDF]

Int J Rheum Dis
ABSTRACT Purpose To determine the association of body mass index (BMI) with incident COVID‐19 infection in patients with inflammatory arthritis (IA) using biologic disease‐modifying anti‐rheumatic drugs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) and to describe characteristics of patients with severe COVID‐19 infection. Methods This prospective
Dhanasekaran P, Yeo SI, Ng YX, Lim R, Wong S, Angkodjojo S, Khor AYK, Koh LW, Lahiri M, Ma M.   +9 more
europepmc   +2 more sources

Golimumab for Polyarticular Juvenile Idiopathic Arthritis and Psoriatic Arthritis: Pharmacologic and Clinical Considerations

Life, 2023
Psoriatic arthritis is a chronic debilitating autoimmune condition, and when diagnosed in patients before the age of eighteen, it is considered pediatric polyarticular juvenile idiopathic arthritis.
Sydney Moore McIntosh, Christian Kerut, Payton P. Hollenshead, Dorothy H. Askins, Kasra Mansourian, Zachary R. Palowsky, Varsha Allampalli, Shahab Ahmadzadeh, Sahar Shekoohi, Alan D. Kaye   +9 more
doaj   +1 more source

Golimumab Therapy in Ulcerative Colitis

The Korean Journal of Gastroenterology, 2016
Ulcerative colitis is a chronic inflammatory condition of the colon, characterized by diffuse mucosal inflammation and blood-mixed diarrhea. The main treatment has been 5-aminosalicylic acid, steroid, thiopurine, and anti-tumor necrosis factor alpha (TNF-
Won Moon
doaj   +1 more source

Early identification of golimumab-treated patients with higher likelihood of long-term retention

Frontiers in Immunology
BackgroundThe early identification of patients’ profiles most likely to respond to and maintain long-term therapy with a biological drug can have clinical and cost-effectiveness implications.ObjectivesTo evaluate the utility of an innovative approach for
Alicia García-Dorta, Enrique González-Dávila, Marta Sánchez-Jareño, Luis Cea-Calvo, Manuel Pombo-Suárez, Fernando Sánchez-Alonso, Isabel Castrejón, Federico Díaz-González, Federico Díaz-González, Federico Díaz-González   +9 more
doaj   +1 more source

Golimumab for Treating Chronic Inflammatory Joint Diseases in the Adult Population: Clinical Efficacy and Tolerability

Вопросы современной педиатрии, 2019
Due to the recent introduction of golimumab into paediatric rheumatology practice, an overview of the clinical studies of this tumour necrosis factor alpha inhibitor, most of which were conducted with adult patients with rheumatic diseases, has been ...
Natal’ya N. Chichasova
doaj   +1 more source